BMS deploys second NVIDIA SuperPOD for AI drug discovery

Bristol Myers Squibb has announced it is deploying its second NVIDIA DGX SuperPOD, built on eight DGX Vera Rubin NVL72 systems, to expand AI-driven drug discovery across its global research organization.

• The new system will be combined with BMS’s existing DGX SuperPOD into a unified environment with a single data plane accessible from every BMS site globally.
• BMS says the new cluster delivers up to 10x performance per megawatt versus the infrastructure it replaces and will support predictions, model training, and agentic workflows across the drug discovery pipeline.
• Researchers will use NVIDIA BioNeMo Agent Toolkit and NVIDIA Mission Control; the company says complex predictions will be initiated in plain English.
• BMS says the earlier DGX SuperPOD has been in use for about three years and has already helped with target identification, CELMoD compound expansion, and lead optimization.
• The article is a company/news-style feature describing a new deployment and related capabilities, not a financial disclosure or pricing announcement.